Home・Elenco Azioni・Ardelyx Inc

Ardelyx Inc

Chiusa

SettoreSettore sanitario

3.76 0.8

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

3.7199999999999998

Massimo

3.91

Metriche Chiave
By Trading Economics
Entrata	21M -17M
Vendite	26M 121M
EPS	-0.07
Margine di Profitto	-13.833
Dipendenti	489
EBITDA	20M -10M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+264.44% upside

Dividendi
By Acuity
Utili prossimi	29 ott 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-182M 1B
Apertura precedente	2.96
Chiusura precedente	3.76

Notizie sul Sentiment di mercato

By Acuity

67%

33%

307 / 340 Classifica in Healthcare

Ardelyx Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

21 ago 2026, 19:16 UTC

Ardelyx Inc shares are higher today, continuing positive momentum since Thursday. No specific news was identified to explain the price movement.

20 ago 2026, 20:01 UTC

News

Ardelyx Inc shares are lower amid a securities investigation into its revised IBSRELA revenue guidance, which was cut to $350-$370 million.

19 ago 2026, 23:01 UTC

Ardelyx Inc. shares are higher in after-market trading, reflecting broader market gains. The stock remains below its 20-day moving average.

18 ago 2026, 23:06 UTC

Ardelyx Inc. shares are roughly flat in after-market trading. The stock is down significantly compared to its month-ago close and below its 20-day moving average.

17 ago 2026, 19:26 UTC

News

Ardelyx shares are lower as Levi & Korsinsky investigates potential federal securities law violations amid reduced revenue guidance for IBSRELA.

14 ago 2026, 23:56 UTC

Ardelyx Inc. shares declined in after-market trading, continuing a broader trend of significant decline over the past month, remaining below the 20-day moving average.

13 ago 2026, 23:01 UTC

Ardelyx Inc. shares advanced modestly in after-market trading, though they remain significantly below the 20-day moving average and near the one-month range's lower end.

12 ago 2026, 23:26 UTC

Ardelyx Inc. shares were trading roughly flat in after-market hours. The stock has declined significantly over the past month amid broader market weakness.

11 ago 2026, 19:56 UTC

Ardelyx Inc's shares are lower today, reflecting a broader decline in the biotechnology sector. Investors monitor macroeconomic factors ahead of the Consumer Price Index report.

10 ago 2026, 23:56 UTC

Ardelyx Inc shares are higher in after-market trading, despite no specific news driving the move. Recent market conditions include cautious optimism following a jobs report.

7 ago 2026, 23:31 UTC

News

Ardelyx shares are higher in after-market trading as TD Cowen maintains a Buy rating and lowers the price target to $10.

6 ago 2026, 23:31 UTC

News

Social Media

Ardelyx Inc. reports Q2 revenue of $118.1 million, missing expectations. Shares decline in after-market trading following revised financial guidance and a net loss of $16.7 million.

3 ago 2026, 19:16 UTC

Ardelyx Inc. shares are trading roughly flat with no specific news identified. The stock remains below its 20-day moving average.

31 lug 2026, 19:16 UTC

Ardelyx Inc. shares are lower, reflecting broader market trends amid rising yields and inflationary pressures, particularly after a notable increase in crude oil prices.

30 lug 2026, 23:51 UTC

Ardelyx Inc. shares are lower in after-market trading, remaining below their 20-day moving average amid broader market weakness.

22 lug 2026, 19:31 UTC

Ardelyx Inc shares are higher in Wednesday's session, continuing a modest rise since Tuesday's close. The stock remains below its 20-day moving average.

20 lug 2026, 19:02 UTC

Ardelyx shares are lower today, reflecting broader weakness in the biotechnology sector. The stock has declined since Friday's close with no specific news identified.

Confronto tra pari

Modifica del prezzo

Ardelyx Inc Previsione

Obiettivo di Prezzo

By TipRanks

264.44% in crescita

Previsioni per 12 mesi

Media 13.63 USD 264.44%

Alto 18 USD

Basso 9 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Ardelyx Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

8 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 8 che hanno fornito valutazioni azionarie a Ardelyx Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

307 / 340 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Ardelyx Inc

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.